Filter     Order  Title asc Title desc Ordering    Display #  5 10 15 20 25 30 50 Item Title Debiopharm and EPFL launch the "Debiopharm Life Sciences Award" The Japanese Cancer Association (JCA) and Debiopharm present the inaugural 2005 JCA-Mauvernay award in Japan Debiovision Inc., a speciality pharmaceutical developer joins the Debio companies Debiovision Inc., anciennement H3 Pharma, un développeur de spécialités pharmaeutiques, se joint au groupe Debio Debiopharm and DeveloGen announce partnering of myasthenia gravis program Debiopharm and Neovacs sign License and Equity Agreement for the development fo Neovacs´ anti-TNF-Alpha product Debiopharm S.A. announces the purchase of all outstanding shares of H3 Pharma Debiopharm S.A. and GPC Biotech AG Announce Partnering of Small Molecule MHC Class II Antagonists Program for Autoimune Diseases Debiopharm S.A. and Tulane Cancer Center nominate Dr T. Curiel and Dr W. Zou, the 2004 Mauvernay Research Excellences Scholars H3 Pharma Inc. and DSM Biologics sign development agreement for SC-1 monoclonal antibody for the treatment of gastric cancer Dyax Corp. and Debiopharm S.A. report positive Results from Phase IIa Clinical Trial with DX-890 (EPI-hNE4) in Children with Cystic Fibrosis Debiopharm S.A. and Dyax Corp. granted orphan drug designation for DX-890 (EPI-HNE4) by U.S. FDA - Cystic Fibrosis designation Debiopharm and Tulane Cancer Center select Hemenway as the 2003 Mauvernay Research Excellence Scholar Debiopharm S.A. and Dyax Corp. granted European Orphan Drug Status for EPI-hNE4 (DX-890) for Cystic Fibrosis Indication DEBIOPHARM S.A. licenses-in a compound from Genodyssee S.A. Debiopharm SA a acquis un nouveau bâtiment à Lausanne et projette de déménager vers la fin 2004 H3 Pharma Licenses in Phase II Product for Stomach Cancer and Acquires Stake in a Human mAb Discovery Company Specializing in Oncology Debiopharm S.A. provides funding to Tulane University Debiopharm S.A. announces a patent application on a hydrosoluble prodrug of cyclosporin A Debiopharm S.A. licenses-in new technology to turn injectable macromolecular drugs into oral formulations   < Prev 1 2 3 Next > Results 21 - 40 of 47

Debio 0827  ( 1 items ) Debio 0826  ( 1 items ) Triptorelin – Trelstar® – Decapeptyl® - Pamorelin®  ( 10 items ) Debio 8609 Sanvar®  ( 13 items ) Debio 025  ( 5 items ) Debio 9902 - ZT-1  ( 9 items ) Debio 0614 (istaroxime)  ( 2 items ) Debio 0507  ( 3 items ) Debio 0719  ( 1 items ) Debio 0617  ( 2 items ) Oxaliplatin – Eloxatin® – Elplat®  ( 10 items ) Moapar® - Salvacyl®  ( 3 items )